Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100

Platelets

Volumn 19, Issue 5, 2008, Pages 335-341

  Madsen, Esben H ^a   Schmidt, Erik B ^a   Maurer Spurej, Elisabeth ^b   Kristensen, Søren R ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Aggregometry; Aspirin; Clopidogrel; Low response; PFA 100; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN;

ABDOMINAL DISCOMFORT; ADULT; ANALYZER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MALE; MEASUREMENT; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; ARACHIDONIC ACID; ASPIRIN; COLLAGEN; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EPINEPHRINE; HUMANS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; REFERENCE VALUES; TICLOPIDINE;

EID: 51849140457     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100801989857     Document Type: Article

References (29)

1. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
4. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C. CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
5. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
6. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
7. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
8. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007.
9. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37-42.
10. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Ilya N, Pres H, Savion H, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
11. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
12. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet J-L, Alessi M-C. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549.
13. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425.
14. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?. J Am Coll Cardiol 2007;49:657-666.
15. Fontana P, Nolli S, Reber G, Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813-819.
16. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92.
17. Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007;121:107-115.
18. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929.
19. Madsen EH, Schmidt EB, Gehr N, Johannesen NL, Kristensen SR. Testing aspirin resistance using the platelet function analyzer-100: Some methodological caveats and considerations. J Thromb Haemost 2008;6:386-388.
20. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, Akyuz U, Unal Dai S, Narin A. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 2007;23:201-206.
21. Poulsen TS, Kristensen SR, Korsholm L, Haghfelt T, Jorgensen B, Licht PB, Mickley H. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 2007;120:477-484.
22. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, Bray PF, Becker LC. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006;98:774-779.
23. van Werkum JW, Kleibeuker M, Mieremet N, Ten Berg JM, Hackeng CM. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: Peak aggregation or late aggregation? J Thromb Haemost 2007;5:884-886.
24. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396.
25. Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005;115:89-94.
26. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547-2552.
27. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerico A, Biagini A. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. Thromb Res 2006;118:487-493.
28. Pamukcu B, Oflaz H, Onur I, Oncul A, Ozcan M, Umman B, Mercanoglu F, Meric M, Nisanci Y. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: A prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 2007;18:187-192.
29. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006;295:1420-1427.